Iovance Biotherapeutics Inc
IOVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.38B
Close$
$-0.19
101.4% downside
Current Fair Value
101.4% downsideOvervalued by 101.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.38 Billion |
|---|---|
| Enterprise Value | $6.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.76 |
| Outstanding Shares | 450,189,000 |
Return
| Return on Equity | -39.33% |
|---|---|
| Return on Assets | -31.62% |
| Return on Invested Capital | -35.73% |
Valuation & Multiples
| P/E Ratio | -19.3 |
|---|---|
| PEG | 33.49 |
| Price to Sales | - |
| Price to Book Ratio | 14.09 |
| Enterprise Value to Revenue | 19.44 |
| Enterprise Value to EBIT | -21.86 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$87.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$115.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 92.13% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 64.37% |
|---|---|
| Total Invested | $332,947▼ 99.97% |
| Investors Holding | 3▼ 302.00% |
ESG Score
No data
About Iovance Biotherapeutics Inc
975 employees
CEO: Maria Fardis Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to id...